Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Infect Dis ; 223(9): 1522-1527, 2021 05 20.
Artículo en Inglés | MEDLINE | ID: mdl-33556961

RESUMEN

BACKGROUND: Guidelines for stopping coronavirus disease 2019 patient isolation are mainly symptom-based, with isolation for 10 to 20 days depending on their condition. METHODS: In this study, we describe 3 deeply immunocompromised patients, each with different clinical evolutions. We observed (1) the patients' epidemiological, clinical, and serological data, (2) infectiousness using viral culture, and (3) viral mutations accumulated over time. RESULTS: Asymptomatic carriage, symptom resolution, or superinfection with a second severe acute respiratory syndrome coronavirus 2 strain were observed, all leading to prolonged infectious viral shedding for several months. CONCLUSIONS: Understanding underlying mechanisms and frequency of prolonged infectiousness is crucial to adapt current guidelines and strengthen the use of systematic polymerase chain reaction testing before stopping isolation in immunocompromised populations.


Asunto(s)
COVID-19/inmunología , Huésped Inmunocomprometido , SARS-CoV-2 , Sobreinfección/virología , Esparcimiento de Virus , Adulto , Anciano , COVID-19/diagnóstico , Prueba de COVID-19/métodos , Humanos , Masculino , Aislamiento de Pacientes
2.
Nat Commun ; 12(1): 5769, 2021 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-34599175

RESUMEN

Distinct SARS-CoV-2 lineages, discovered through various genomic surveillance initiatives, have emerged during the pandemic following unprecedented reductions in worldwide human mobility. We here describe a SARS-CoV-2 lineage - designated B.1.620 - discovered in Lithuania and carrying many mutations and deletions in the spike protein shared with widespread variants of concern (VOCs), including E484K, S477N and deletions HV69Δ, Y144Δ, and LLA241/243Δ. As well as documenting the suite of mutations this lineage carries, we also describe its potential to be resistant to neutralising antibodies, accompanying travel histories for a subset of European cases, evidence of local B.1.620 transmission in Europe with a focus on Lithuania, and significance of its prevalence in Central Africa owing to recent genome sequencing efforts there. We make a case for its likely Central African origin using advanced phylogeographic inference methodologies incorporating recorded travel histories of infected travellers.


Asunto(s)
COVID-19/transmisión , COVID-19/virología , SARS-CoV-2/genética , África Central/epidemiología , Anticuerpos Neutralizantes/inmunología , COVID-19/epidemiología , Europa (Continente)/epidemiología , Humanos , Evasión Inmune/genética , Mutación , Filogenia , Filogeografía , SARS-CoV-2/clasificación , SARS-CoV-2/inmunología , Glicoproteína de la Espiga del Coronavirus/genética , Viaje/estadística & datos numéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA